Short answer
Emergent BioSolutions Inc. (EBS) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $231M (down 21.3% year over year) with net income of $51M.
Q3 2025 key financials · XBRL
- Revenue
- $231M
- −21.3% YoY · +64.0% QoQ
- Net income
- $51M
- −55.4% YoY · +526.7% QoQ
- Operating margin
- 33.1%
- EPS (diluted)
- $0.90
- −59.1% YoY · +550.0% QoQ
Source: XBRL data from the Emergent BioSolutions Inc. (EBS) Q3 2025 10-Q on SEC EDGAR. USD.
Emergent BioSolutions Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $231.1M, down 21% YoY from $293.8M
- Gross margin 54% vs 51% YoY, with gross margin $119.8M vs $144.9M
- Best segment Other Products revenue $57.5M, up 91% YoY; worst Smallpox MCM $83.6M, down 37%
- Operating income $76.5M, up 19% YoY from $64.5M
- Capital deployment: $8.9M share repurchases and $5.8M Senior Note repurchases in the quarter
Risk Factors
- New divestiture risk triggered by Baltimore-Bayview sale to Syngene for approximately $36.5 million on March 19, 2025
- Retained divestiture liabilities, buyer indemnities, and disputes could exceed expectations and pressure cash flows
- Strategic transaction risk: milestone receipts include up to $80.0 million from CHIKV VLP and $30.0 million tied to 2026 Vaxchora and Vivotif sales
- Share-repurchase risk: $15.8 million used through September 30, 2025 under the $50.0 million authorization
- Market risk: repurchases may occur at unfavorable prices or fail to enhance long-term stockholder value
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Emergent BioSolutions Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.